Back to Browse Journals » Patient Preference and Adherence » Volume 2

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

Authors Sunanda Kane, William Holderman, Peter Jacques, Todd Miodek

Published 22 September 2008 Volume 2008:2 Pages 253—258

DOI https://dx.doi.org/10.2147/PPA.S3698

Review by Single-blind

Peer reviewer comments 2

Sunanda Kane1, William Holderman2, Peter Jacques2, Todd Miodek3

1Mayo Clinic College of Medicine, Rochester, MN, USA; 2Digestive Health Specialists, Tacoma, WA, USA; 3University of Chicago, Chicago, IL, USA

Background and Aims: Multiple studies have demonstrated the efficacy of aminosalicylates in maintaining remission in ulcerative colitis (UC). A newer formulation of mesalamine can be administered once daily. We aimed to examine the efficacy and tolerability of pH-dependent mesalamine for long-term maintenance, and compare the rates of medication consumption between groups over a prolonged period.

Methods: Subjects whose UC had been quiescent for at least 4 months, and who had been receiving mesalamine for maintenance only, were randomized to once daily or conventional dosing for 12 months. Disease activity and medication consumption was assessed every 3 months. The primary endpoint was the percentage of those with quiescent disease at 12 months.

Results: We enrolled 20 patients, 12 to once daily and 8 to conventional dosing. Six of the 12 patients (50%) in the once daily group compared with 5 of the 8 patients (62.5%) in the conventional group experienced a flare (p = 0.31). Only 5 of the 12 (42%) patients in the once daily group were adherent compared with 3 of 8 patients (37.5%) in the conventional dosing group (p = NS). Median amount consumed in the once daily group was 63% (range 0%–100%) and in the conventional group 55% (range 0%–100%), (p > 0.5). None of the adherent subjects in the once daily group experienced a flare, while 6 out of 7 (86%) who were non-adherent experienced a flare (p < 0.01). In the conventional dosing group, 1 in 3 adherent patients (33%) experienced a fl are compared with 4 out of 5 (80%) in the non-adherent group (p < 0.01).

Conclusion: Adherence, rather than medication regimen, appeared to be important in disease outcome at 12 months.

Keywords: ulcerative colitis, mesalamine, aminosalicylates, remission

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence

Steven J Bernick, Sunanda Kane

Patient Related Outcome Measures 2010, 1:57-63

Published Date: 15 June 2010

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Advances in cancer pain from bone metastasis

Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY

Drug Design, Development and Therapy 2015, 9:4239-4245

Published Date: 18 August 2015

Targeting the hypoxia pathway to treat pancreatic cancer

Erickson LA, Highsmith Jr WE, Fei P, Zhang J

Drug Design, Development and Therapy 2015, 9:2029-2031

Published Date: 8 April 2015

Colorectal cancer in Chinese patients: current and emerging treatment options

Li L, Ma BBY

OncoTargets and Therapy 2014, 7:1817-1828

Published Date: 4 October 2014

The potential clinical applications and prospects of microRNAs in lung cancer

Gao Y, Gao F, Ma JL, Sun WZ, Song LP

OncoTargets and Therapy 2014, 7:901-906

Published Date: 4 June 2014

Clinical epidemiology of epithelial ovarian cancer in the UK

Doufekas K, Olaitan A

International Journal of Women's Health 2014, 6:537-545

Published Date: 23 May 2014

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Yee AJ, Raje NS

Clinical Interventions in Aging 2012, 7:331-338

Published Date: 3 September 2012

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

Shodeinde AL, Barton BE

OncoTargets and Therapy 2012, 5:119-125

Published Date: 4 July 2012

Use of administrative hospital registry data and a civil registry to measure survival and other outcomes after cancer

Sørensen HT, Lash TL

Clinical Epidemiology 2011, 3:1-2

Published Date: 21 July 2011

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011